Galapagos NV: Galapagos to present new data from long-term e

Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib

Related Keywords

United Kingdom , Mechelen , Region Flamande , Belgium , Japan , Canada , Northern Ireland , Craigavon , London , City Of , Japanese , Great Britain , Daniele Dambrosio , Dennis Riedl , Ailsa Hart , Roberta Loveikyte , Kristina Harris , Pieter Jan Stiers , Katrien Van Beneden , Van Gijsel , Briang Feagan , Takayuki Matsumoto , Andreas Sturm , Christine Rudolph , Hannah Knight , Eva Santermans , Brian Feagan , Stefan Schreiber , Fatima Dawod , Tadakazu Hisamatsu , Karine Muller , Roger Rolph , Marieke Vermeersch , Edouard Louis , Sandra Cauwenberghs , Taku Kobayashi , Johan Burisch , Alessandra Oortwijn , Paul Van Hoek , Alessandro Armuzzi , Sarah Weatherby , Laurent Peyrin Biroulet , Corinne Jamoul , Katsuyoshi Matsuoka , Gerhard Rogler , Elisa Chenailler , Bart Eskens , Colitis Organization , Exchange Commission , Japanese Ministry Of Health , Twitter , European Union , European Medicines Agency , Gilead Sciences Inc , European Crohn , Mayo Clinic Score , Danieled Ambrosio , Therapeutic Area Head , Inflammatory Bowel Disease , Western University , Ulcerative Colitis , Margaux Faes , Angela De Haas , Poster Exhibition , Meulen De Jong , Rachael Meadows , European Summary , Product Characteristics , Great Britain Summary , Northern Ireland Summary , Japanese Ministry , Gilead Sciences , Inflammatory Bowel Disease Questionnaire , Galapagos , Present , Data , Rom , Song , Term , Extension , Study , Filgotinib , Ulcerative , Colitis , Nnual , Cco , Congress , 023 ,